Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today said that Becki Morison will join the company, effective October 1 in the position of executive vice president, global therapeutics and value strategy. 23 September 2020
Biotechnology
The US Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), respectively, for its interleukin (IL)-17 inhibitor bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. 23 September 2020
Pharmaceutical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) at its September meeting recommended label indication extensions for a total of 15 already-marketed drugs, the most notable of which are the following four. 19 September 2020
Pharmaceutical
Raziel Therapeutics, an Israel-based pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, has licensed its disruptive technology, RZL-012, to Fosun Pharma. 17 September 2020
Biotechnology
Shares in London-based Amryt Pharma were up around 50% in morning trading on Tuesday, following positive top-line results from a Phase III study of Filsuvez (oleogel-S10), a topical therapeutic gel. 9 September 2020
Biotechnology
Shares of UK biotech Allergy Therapeutics jumped 7.8% to 19.40 pence in early trading after it revealed a further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field. 3 September 2020
Pharmaceutical
Danish privately-held dermatology specialist LEO Pharma announced the sale of a portfolio of four non-core products to Germany’s Cheplapharm Arzneimittel for 300 million euros ($357 million). 1 September 2020
Pharmaceutical
Foreign drugs continue to disappear from the Russian pharmaceutical retail, posing a threat of a shortage of medicines that could be recommended for the treatment of some serious diseases, according to recent studies prepared by some local market research agencies and pharmaceutical business analysts, reports The Pharma Letter’s local correspondent. 1 September 2020
Pharmaceutical
The first novel medicine for acne in decades has been approved in the USA, lifting shares in Italian developer Cassiopea 16% on Thursday, and a further 6% on Friday morning. 28 August 2020
Pharmaceutical
Dermavant Sciences, a dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has announced positive results from the Phase III PSOARING 1 and PSOARING 2 studies. 27 August 2020
Pharmaceutical
Massachusetts, USA-based DUSA Pharmaceuticals, a subsidiary of India’s Sun Pharmaceutical Industries, has agreed a settlement with the US Department of Justice (DoJ). 25 August 2020
Biotechnology
Sino-American outfit Connect Biopharma is $115 million better off after a Series C financing. 24 August 2020
Biotechnology
Shares of US biotech Regeneron Pharmaceuticals were up 3% before the bell, but after the company posted what were better than expected second-quarter 2020 financial results, the stock dipped 1.36% to $639.63. 5 August 2020
Biotechnology
Shares of US biotech Incyte were down 3.5% at $ 98.25 by early afternoon today, after it reported 2020 second quarter financial results. 4 August 2020
Biotechnology
The US Food and Drug Administration has approved an expanded indication for Stelara (ustekinumab) as a treatment for pediatric patients (six-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis (PsO). 31 July 2020
Biotechnology
AbbVie’s aspiring blockbuster Rinvoq (upadacitinib) is on course for a second indication following the presentation of pivotal Phase III results in atopic dermatitis (AD). 28 July 2020
Pharmaceutical
Shares in Spanish drugmaker Almirall were 1.5% lower as Monday’s trading day neared its end in Europe. 27 July 2020
Biotechnology
UCB today announced positive results from the Phase IIIb BE RADIANT study, a direct comparison of the investigational interleukin (IL)-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Novartis’ (NOVN: VX) Cosentyx (secukinumab) in the treatment of adult patients with moderate-to-severe plaque psoriasis. 24 July 2020
Pharmaceutical
LEO Pharma’s UK and Ireland business has appointed a new medical affairs lead, Amit Aggarwal, formerly director of UK medical affairs at Bayer. 23 July 2020
Pharmaceutical
Privately-held Danish company MC2 Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Wynzora Cream (calcipotriene and betamethasone dipropionate) for once-daily topical treatment of plaque psoriasis in adults. 22 July 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze